Jessica Scales, PhD, of the Melanoma Research Alliance, discussed the new RARE Registry data report and dermatologists’ role ...

Mark Lebwohl, MD, describes his approach on when to start systemic therapy, access considerations, and dupilumab safety and ...

One clinical trial widened a patient's time in the sun, yet fear of hidden light sources remained. The conversation also ...

Two oral trial drugs changed one patient's daily life, culminating in his first beach visit without protective gear. He and ...

Diego Ruiz Dasilva, MD, and Lindsey Finklea, MD, discuss the burden of chronic inducible urticaria and phase 3 REMIND findings for remibrutinib.

Trickett and Neita compare adalimumab, secukinumab, and bimekizumab trial data and explain how comorbidities guide biologic ...

An 83-year-old patient's three-decade psoriasis journey, shaped by a comorbid MGUS diagnosis and a hospitalization that ...

Dermatology Times is looking back on the top stories in dermatology from the month of October. From major data presented at ...

Doral Fredericks, PharmD, MBA, discusses how life stages, mental health, and reproductive concerns can shape dermatologic care for women.

Clinician FAQ on remibrutinib's FDA approval in symptomatic dermographism: RemIND efficacy, mechanism, safety, and supporting ...

Lutikizumab (ABT-981) met its primary end point and all 8 ranked secondary end points in the phase 3 INTREPID trial ...

Oral JAK inhibitors are preferred first-line long-term therapy for severe adult AA; FDA-approved agents are favored, whereas dupilumab is an alternative for patients with comorbid atopy. Experts ...